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s aIntroduction: This study examined hydroxyurea usage in young children with sickle cell anemia
within New York State (NYS). The cohort was 273 children with sickle cell anemia born in NYS in
2006–2009 and enrolled essentially continuously in Medicaid for the ﬁrst 4 years of life.
Methods: Medicaid data were used to examine hydroxyurea usage in this group by age at ﬁrst
prescription ﬁll, persistence, region, treatment institution, and year. Log-binomial regression models
were used to estimate the likelihood of receiving hydroxyurea treatment. Data from birth through
2014 for all members of the study group were assembled and analyzed in 2015.
Results: About 25% of the cohort had at least one ﬁlled hydroxyurea prescription by their ﬁfth
birthday, and nearly 40% by the end of the study period. The mean proportion of days covered for
the ﬁrst year of therapy was 56.3%. Adherence was also assessed by calculating medication
possession ratios for individual treatment periods. Slightly more than one third of treated children
showed 80% coverage by these measures. There was a consistent, but not statistically signiﬁcant,
trend toward younger age at ﬁrst ﬁll. Signiﬁcant regional and treatment center differences in
initiation of hydroxyurea use, but not in persistence after initiation, were noted among NYS centers.
Conclusions: Subsequent to clinical studies demonstrating safety, current NYS-wide use of
hydroxyurea in young children with sickle cell anemia appears to be widespread and increasing.
However, practice differences between treatment centers and inadequate adherence may limit the
full disease-modifying effects of hydroxyurea.
(Am J Prev Med 2016;51(1S1):S31–S38) & 2016 American Journal of Preventive Medicine. Published by
Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).IntroductionHydroxyurea (HU) was approved by the U.S.Food and Drug Administration in 1998 for usein adult patients with sickle cell anemia (SCA).
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rticle under the CC BY-NC-ND license (http://creativecoRCTs and nearly 20 years of clinical experience have
demonstrated its safety and efﬁcacy.1–4 Beneﬁts for adult
patients include fewer pain crises, lower rates of acute
chest syndrome, reduced need for blood transfusion,
reduced hospitalization, and reduced mortality with
long-term use. Clinical trials and observational studies
also examined potential beneﬁts of HU use in adoles-
cents, children, and infants.5–12 Findings demonstrated
beneﬁts similar to those seen in adults. Longer-term
studies indicated sustained beneﬁts without excessive
toxicity, effects on growth, or development.6,13–16 The
strength of evidence supporting the beneﬁts and safety of
HU use in pediatric patients led the most recent expert
panel on Evidence-Based Management of Sickle Cell
Disease to recommended that all pediatric patients with
SCA aged 9 months and older be offered HU treatment,
even though U.S. Food and Drug Administration appro-
val does not yet extend to pediatric use.17–19
This study was undertaken to better deﬁne the
population of young children with SCA in New Yorkier Inc. This is an
mmons.org/licenses/by-nc-nd/4.0/).
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to determine the extent of use, whether treatment
patterns have changed over time, and if there are regional
or treatment center differences in use of HU in NYS that
may reﬂect different adoption rates or barriers to use.20,21
Because the majority of children with SCA are covered by
public insurance, Medicaid data were used to examine
HU use in a well-deﬁned group of children with SCA,
born in NYS in 2006–2009, from birth through 2014.22
Methods
Study Population
The study population consisted of 273 children born in NYS in
2006–2009 with homozygous sickle cell anemia (HbSS), matched
with corresponding NYS Medicaid records, and enrolled in
Medicaid for at least 45 of their ﬁrst 48 months from birth. In
NYS, newborns with sickle cell disease are referred by the Newborn
Screening Program (NBS) to Department of Health–designated
hemoglobinopathy specialty centers for conﬁrmatory diagnosis and
treatment (www.wadsworth.org/newborn-screening/sickle-cell-di
sease-ss). Children included in the study group had a conﬁrming
laboratory result upon referral to a designated treatment center or,
in the few cases lost to follow-up by NBS, had extensive Medicaid
history supporting the NBS ﬁnding. Individuals with conﬁrmed
diagnosis of HbSβ0-thalassemia were not included. A corresponding
cohort of children born in NYS with sickle disease with hemoglobins
S and C (HbSC) in the same years was assembled for comparative
analyses. NBS records were matched to Medicaid data using Salient
Interactive Miner, version 5.70, to query the most current data sets
hosted by Salient. The study population was established in 2015. This
study was approved by the NYS Department of Health’s IRB.
Measures
Medicaid enrollment and demographic information (enrollment
months, birth year, sex, race, residential and institutional region)
were compiled from Medicaid records using Salient. HU usage was
determined using Medicaid drug claims data searching for all HU
drug codes (national drug codes 3083050, 3633517, 3633617, 3633717,
54224725, 555088202, 38779135408, 49884072401, 51927265500,
68084028401). In addition, some HU prescription ﬁlls prior to 2012
prepared as liquid mixtures were reported in the Medicaid record as
“Compound” (national drug code 99999999999); these were included
in the analysis when it could be determined they were HU. Filled HU
prescriptions and days of drug supply were assessed for all members’
enrolled months through calendar year 2014.
Initiation of HU therapy was deﬁned as the ﬁrst HU prescription
ﬁll. Geographic distribution of residence or treatment center was by
New York City (NYC) borough and Long Island (LI), with all other
non-NYC/LI counties grouped as rest of state (ROS). Differences in
initiation, adherence, and persistence of HU therapy were measured
according to the locations of treatment centers, selected treatment
center groups, and the number of treatment centers the children
received sickle cell–related care from. Persistence was calculated by
ﬁrst-year (the sum of days drug supply for the 365 days after ﬁrst
ﬁll/365) and overall proportion of days covered (PDC; the sum of
days drug supply / days elapsed from ﬁrst ﬁll to end of study –missing enrollment days).23 Adherence was measured by calculat-
ing medication possession ratios (MPRs) for the therapeutic period,
spanning the ﬁrst and last ﬁll (calculated as sum of supply days/days
elapsed between ﬁrst and last ﬁll þ days last ﬁll – missing
enrollment days).23 For regional analyses, assignments were based
on the most recent recipient county of residence. For treatment
center analyses, claims data were reviewed for each recipient,
assessing SCA-related inpatient stays, emergency department visits,
outpatient visits, provider afﬁliations, and associated sickle cell–
related diagnoses, prescriptions, and procedures. Individuals were
assigned as either (1) receiving their care solely or primarily from a
deﬁned, single treatment center and associated groups of providers
(“Single”) or (2) receiving their care from more than one treatment
center and associated groups of providers (“Multiple”).
Data were collected for the analysis in mid-2015, and included
information from birth through 2014 for all individuals in the
study group.
Statistical Analysis
Statistical analyses were performed using SAS, version 9.4.
Descriptive analyses were done for the demographic distribution.
Chi-square tests were used in the comparisons of the distributed
differences of sex, race, and birth year between HU users and non-
HU users. Fisher exact test was conducted in the comparison of the
distributed difference of county/borough of residence between HU
users and non-HU users. Log-binomial regression was conducted
in HU initiation analyses of the SCA cohort. Relative risks and 95%
CIs were reported. Multiple linear regression was used in the HU
persistence analyses. PDC within 365 days after the ﬁrst ﬁll, overall
PDC, MPR, and their 95% CIs were reported.
Results
Approximately 80% of 527 children born with a con-
ﬁrmed NBS SCA diagnosis in NYS in 2006–2009 could
be matched to Medicaid records. Of these, 273 were
enrolled at least 45 of their ﬁrst 48 months of life and
formed the cohort used for this study. Medicaid enroll-
ment continued through 2014 for all but three members
of this cohort who received HU, and for 92% of all 273
members, enabling the authors to follow most for the
entire study period.
The sexes were evenly divided (51.6% male), and race
in Medicaid records was 93.8% black or African Amer-
ican (Table 1). This value included non-Hispanic black
members (72.9%) plus all those reporting black under race
combinations. Members were evenly distributed across
birth years, and the majority resided in NYC and LI
(82.8%). Individuals from each NYC borough and LI, and
from a number of counties in ROS, received HU therapy.
Overall, 39.6% (108/273) were initiated on HU therapy
by the end of 2014. No signiﬁcant differences in this
parameter were found by sex, race, or birth year
(Table 1). Only three of 150 members (2%) of the
corresponding cohort of children with HbSC had been
treated with HU by the end of 2014.www.ajpmonline.org
Table 1. Demographic Characteristics of Study Group
HU usage
Characteristic SCA cohort overall, n (%)a HU user, n (%)b Non-HU user, n (%)b p-value
Study population 273 (100) 108 (39.6) 165 (60.4)
By sex 0.4252
Male 141 (51.6) 59 (41.8) 82 (58.2)
Female 132 (48.4) 49 (37.1) 83 (62.9)
By race 0.3769
Black or African American 256 (93.8) 103 (40.2) 153 (59.8)
Otherc 17 (6.2) 5 (4.6) 12 (7.3)
By birth year 0.1293
2006 67 (24.5) 34 (50.8) 33 (49.3)
2007 62 (22.7) 21 (33.9) 41 (66.1)
2008 66 (24.2) 27 (40.9) 39 (59.1)
2009 78 (28.6) 26 (33.3) 52 (66.7)
By residence county/borough o0.0001
Bronx 87 (31.9) 29 (33.3) 58 (66.7)
Brooklyn 71 (26.0) 25 (35.2) 46 (64.8)
Manhattan 15 (5.5) 7 (46.7) 8 (53.3)
Queens 29 (10.6) 9 (31.0) 20 (69.0)
Staten Island 8 (2.9) 2 (25.0) 6 (75.0)
Long Island 10 (3.7) 3 (30.0) 7 (70.0)
Rest of State 47 (17.2) 32 (68.1) 15 (31.9)
Unknown 6 (2.2) 1 (16.7) 5 (83.3)
Note: Boldface indicates statistical signiﬁcance (po0.05).
aColumn percent.
bRow percent.
cOther included all others whose Race Combination did not include black.
HU, hydroxyurea; SCA, sickle cell anemia.
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received care at centers in NYC and LI (Table 2). Roughly
80% of children received SCA-related care in their
county/borough of residence. Most (205/273, 75.1%)
received all or almost all of their SCA-related care from
a single treatment center (including afﬁliated sites and
providers) (Table 2). Almost all of the children (approx-
imately 98%) received their care from one or more of the
approximately 30 NYS-designated treatment centers (the
number varied during the study; currently there are 28).
Thus, the designated centers likely are major providers of
sickle cell–related care from birth throughout childhood.
Individuals treated at centers in NYC and LI (relative
risk, 0.4939; 95% CI¼0.3778, 0.6458) were signiﬁcantly
less likely to have received at least one HU ﬁll, compared
with individuals who received treatment in ROS (33.6%July 2016vs 68.1%) (Table 2). Moreover, children treated in any of
the NYC boroughs except Manhattan, or in more than
one borough, were also statistically less likely to have
received an HU ﬁll than the children receiving treatment
in ROS. The difference in initiating HU treatment
between those treated at a single center and those at
multiple centers was minimal.
Treatment of study group members was not distrib-
uted evenly among the centers. Ten of the about 30
treatment centers (two of them ROS) were found to
provide SCA-related care for ten or more members of the
study group. Together, these top ten centers accounted
for 157 of the 205 children who received SCA care from a
single center (475%). Other centers were the primary
source of SCA care for one to seven study members. Six
treatment centers located in NYC, which together were
Table 2. Analysis of Initiation of HU Treatment
Variable SCA, n HU, n HU user rate, % RR (95% CI) p-value
SCA cohort 273 108 39.6
By treatment region
NYC/Long Island 226 76 33.6 0.4939 (0.3778, 0.6458) o0.0001
ROS 47 32 68.1 ref —
By treatment county/borough
Bronx 70 22 31.4 0.4616 (0.3102, 0.6870) 0.0001
Brooklyn 67 25 37.3 0.5480 (0.3797, 0.7910) 0.0013
Manhattan 27 12 44.4 0.6528 (0.4101, 1.0392) 0.0722
Long Island 26 8 30.8 0.4519 (0.2458, 0.8308) 0.0106
Othera 7 1 14.3 0.2098 (0.0338, 1.3016) 0.0936
Multiple counties/boroughs 29 8 27.6 0.4052 (0.2177, 0.7542) 0.0044
ROS 47 32 68.1 ref —
By single or multiple center(s)
Single 205 84 41.0 1.1610 (0.8089, 1.6663) 0.4182
Multiple 68 24 35.3 ref —
By treatment at
Low-prescribing NYC centers 27 2 7.4 0.1004 (0.0261, 0.3855) 0.0008
All other NYC/LI centers 137 51 37.2 0.5044 (0.3808, 0.6689) o0.0001
Multiple centers 67 24 35.8 0.4853 (0.3360, 0.7010) 0.0001
ROS centers 42 31 73.8 ref —
Note: Boldface indicates statistical signiﬁcance (po0.05).
aStudy members who received treatments in Staten Island or Queens were combined as “Other” due to the small number.
HU, hydroxyurea; LI, Long Island; NYC, New York City; ROS, rest of state; SCA, sickle cell anemia.
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this study, combined had only two members with ﬁlled
HU prescriptions (7.4%). A substantial fraction of older
children, born prior to 2006, with SCA diagnoses
reported to Medicaid and seen by the providers at these
centers, did have HU ﬁlls during the study period,
arguing that the lower initiation rate for the younger
children in this study group was not simply due to failure
to report on Medicaid claims. Separating this small group
of low-prescribing centers from the NYC and LI group
left a statistically signiﬁcant difference in initiation of
treatment between the remaining NYC and LI centers,
and ROS (Table 2). Moreover, each of the three largest
ROS centers had higher HU therapy initiation rates than
any one of the major NYC/LI centers providing treat-
ment to this group.
Figure 1 depicts the timing (by recipient age in days, y-
axis) and distribution of HU prescription ﬁlls (closed
circles), plus enrollment months (shaded squares), for
the 108 individuals (x-axis) in the study with at least oneHU ﬁll by the end of 2014. The number of HU
prescriptions ﬁlled per individual ranged from a mini-
mum of one to maximum of 62, with a mean of 17 and
median of 13. Almost 90% of all ﬁlls were reported as a
30-day supply. The mean days of coverage were 480, with
a median of 367, and total coverage days ranged from 28
to 1,915.
All members of the study group had reached their ﬁfth
birthday (1,825 days) by the end of the study period, and
69 (25.3%) had a ﬁrst ﬁll by then. The percentage of
children in the study group who had received a ﬁrst HU
ﬁll by age 5 years trended upward by birth year, from a
low of 21% in 2007 to 31% in 2009. Correspondingly, age
at ﬁrst ﬁll trended younger over the study period. Of
those who received their ﬁrst ﬁll before age 5 years, the
average ages at ﬁrst ﬁll were: 46 months for those born in
2006, 42 months for those born in 2007, 41 months for
those born in 2008, and 37 months for those born in 2009
(Figure 1). However, neither of these trend measures
achieved statistical signiﬁcance (p¼0.1205 for age at ﬁrstwww.ajpmonline.org
Figure 1. Hydroxyurea prescription ﬁlls and enrollment datafor each of the 108 individuals with at least one prescription ﬁlled
during the study period.
Note: Each vertical bar represents ages at HU prescription ﬁlls (black circles) and at the beginning of each enrollment month (gray rectangles) for one
of the 108 study members who received HU treatment. Most HU prescription ﬁlls covered 30 days (see text). Enrollment gaps and termination of
enrollment are visible as open segments in individual bars.
HU, hydroxyurea.
Anders et al / Am J Prev Med 2016;51(1S1):S31–S38 S35ﬁll), given the small numbers receiving early HU for each
birth year.
Persistence (whether a patient stays on therapy) of HU
therapy was assessed by ﬁrst-year PDC (Table 3).23 Those
whose ﬁrst ﬁll was in 2014 were excluded from this
measure owing to insufﬁcient remaining days after ﬁrst
ﬁll. The mean ﬁrst-year PDC for the eligible members of
the study group was 56.3%, or 206 days. Only 30 of 88
(34.1%) had 292 days (80%) or more ﬁrst-year coverage.
To examine longer-term usage, an overall PDC from the
date of ﬁrst ﬁll to the end of study, excluding missing
enrollment days, was also calculated. The mean overall
PDC dropped to 47.8%, consistent with the observation
that many recipients stopped therapy prior to the end of
the study period or ending Medicaid enrollment
(Figure 1). Adherence (whether the patient takes medi-
cation according to schedule during treatment) was
calculated as an MPR.23 The mean MPR was 67.8%,
with values ranging from 9.3% to 100%. Slightly more
than one third of those receiving HU, 34 of 95 (35.8%),
had an MPR of Z80%. The fraction of individuals with
80% MPR was similar to that with 80% ﬁrst-year PDC.
No signiﬁcant differences were found between ROS
and NYC/LI PDC values for the ﬁrst year, or overall,
whether analyzed by county/borough, single or multiple
treatment centers, or selected treatment center groups
(Table 3). Patients treated at multiple centers were found
marginally more adherent compared with patients whoJuly 2016received treatment from ROS centers (p¼0.036) by the
MPR measure but not by the PDC measure, suggesting
this is not a meaningful difference. Thus, adherence and
persistence of HU treatment after initiation appeared
similar for ROS and NYC/LI.
Discussion
Treatment with HU, in combination with established
preventative measures, is an important component of
efforts to improve outcomes for children with SCA.17,18
This study used NBS cohorts to examine HU use for
young children with SCA in NYS. Demographics were
typical of the sickle cell population in NYS, with a slightly
higher proportion of black or African American mem-
bers than previously reported, which likely reﬂects differ-
ences in reporting of race and ethnicity in Medicaid
compared with the sources used for the previous
studies.24–26 Linking NBS results directly to Medicaid
allowed genotype-speciﬁc analyses. A further strength of
this study is that it compared rates of initiation and
persistence of HU therapy across NYS geographic
regions and among providing centers.
Limitations
This study utilized administrative claims data solely to
characterize care and is subject to its attendant limita-
tions.27 Although these data are considered to be a
Table 3. Analysis of Persistence and Adherence to HU Treatmenta
First year proportion of days covered
(of 365 days from ﬁrst-ﬁll) Overall proportion of days covered Medication possession ratio
Variable nb % (95% CI) p-value % (95% CI) p-value nc % (95% CI) p-value
SCA cohort 88 56.3 (49.3, 63.3) 47.8 (41.1, 54.6) 94 67.8 (62.6, 73.1)
By treatment region
NYC/Long Island 63 57.2 (48.5, 65.9) 0.255 44.8 (36.7, 52.8) 0.473 66 69.9 (63.6, 76.1) 0.125
ROS 25 54.0 (42.2, 65.8) ref 55.6 (43.1, 68.2) ref 28 63.0 (53.1, 73.0) ref
By treatment county/borough
Bronx 20 48.8 (31.2, 66.5) 0.810 34.5 (20.4, 48.6) 0.121 18 66.3 (51.7, 81.0) 0.371
Brooklyn 20 55.9 (39.9, 71.8) 0.488 45.8 (29.9, 61.8) 0.566 23 70.3 (58.4, 82.2) 0.219
Manhattan 11 69.9 (48.8, 91.0) 0.183 63.6 (42.6, 84.6) 0.495 12 72.3 (57.5, 87.1) 0.279
Long Island 7 56.8 (21.6, 91.9) 0.388 31.9 (13.0, 50.7) 0.344 7 66.3 (47.9, 84.8) 0.682
Multiple counties/boroughs 5 69.2 (35.6, 102.7) 0.290 58.0 (21.7, 94.4) 0.917 6 78.0 (60.2, 95.8) 0.115
ROS 25 54.0 (42.2, 65.8) ref 55.6 (43.1, 68.2) ref 28 63.1 (53.1, 73.0) ref
By single or multiple center(s)
Single 68 53.9 (46.1, 61.7) 0.145 46.0 (38.4, 53.6) 0.278 73 65.7 (59.6, 71.8) 0.061
Multiple 20 64.5 (48.1, 80.9) ref 54.1 (38.6, 69.6) ref 21 75.1 (64.9, 85.3) ref
By treatment at
NYC/LI centers 44 54.3 (43.9, 64.7) 0.338 40.9 (31.6, 50.2) 0.377 46 67.4 (59.5, 75.2) 0.322
Multiple centers 20 64.5 (48.1, 80.9) 0.083 54.1 (38.6, 69.6) 0.686 21 75.1 (64.9, 85.3) 0.036
ROS centers 24 53.2 (41.0, 65.4) ref 55.3 (42.2, 68.4) ref 27 63.0 (52.7, 73.3) ref
Note: Boldface indicates statistical signiﬁcance (po0.05).
aModels adjusted by birth year.
bn¼number of patients who had a full year in study period after ﬁrst ﬁll of HU.
cn¼number of patients who had two or more ﬁlls of HU in the study period.
HU, hydroxyurea; LI, Long Island; NYC, New York City; PDC, proportion of days covered; ROS, rest of state; SCA, sickle cell anemia.
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drug effects, limitations include: the potential for missing
data (e.g., for children enrolled in clinical trials or in
foster care); reliance on the days of drug supply reported
by the claims; incorrect reporting of medication form
(liquid versus capsule); and possible days of use beyond
possession.28,29 This latter may be particularly problem-
atic when dosage adjustments are necessary, such as early
in therapy, and as children grow, and may result in less
reliable persistence estimates. Dosages indicated in Med-
icaid HU claims data did not appear reliable for
determining administered dosages, perhaps because in
many cases the reported dosage form (capsule) was
prepared to administer as a liquid. Also, treatment center
assignments were made solely on the basis of Medicaid
claims data over the entire study period. Finally, this
study is limited to children born in 2006–2009 enrolled
in NYS Medicaid and may not be directly applicable to
other age groups, geographic areas, or systems of
health care.
Conclusions
This analysis provides data to conclude that HU is used
by specialty centers throughout NYS to treat young
children with SCA, including children aged younger
than 5 years. Of the approximately 30 designated treat-
ment centers, 20 were found to have prescribed HU for at
least one study member, and several others cared for no
or very few members of this study group. Nevertheless,
regional and treatment center–speciﬁc differences were
observed. Study members living in NYC and LI were
signiﬁcantly less likely to receive HU than those residing
in ROS. A few treatment centers did not use HU for
treatment of young children in this study group. How-
ever, these low-prescribing treatment centers did not
account for the signiﬁcant regional differences. Because
the majority of children in NYS with SCA reside in NYC,
this ﬁnding suggests that additional children could
potentially beneﬁt from HU therapy. On the other hand,
no meaningful regional differences in persistence or
adherence were found among those who initiated treat-
ment. Only about one third of children initiated on HU
showed 80% coverage, typically considered adequate, by
either PDC or MPR measures.
Only a few other studies have used Medicaid data to
assess HU use in community health settings, none of
which examined usage in NYS, and all relied on claims-
based diagnoses for cohort selection. South Carolina
Medicaid data were used to examine the impact of HU
treatment on clinical complications of pediatric SCA
patients during the decade ending in 2006.30 In that
study, only 8% of the included pediatric SCA patientsJuly 2016were found to have been treated with HU. Another study
examined HU use in the adult Florida Medicaid pop-
ulation for 2001–2005, ﬁnding that 38% of those with
three or more hospitalizations for crisis had ﬁlled at least
one HU prescription.31 However, only 15.4% of the HU
group had an MPR of 80% or greater. More recently,
North Carolina Medicaid data for 2000–2008 were used
to examine HU adherence and associated outcomes
among 312 SCA patients of all ages, with a median age
at index date of about 21 years.32 In that study, about 35%
of users were found to be adherent (80% or greater MPR),
similar to the rates found here, and adherence was found
to correlate with improved outcomes. The apparent low
adherence rates found in the present study suggest
adherence and persistence remain a challenge to achiev-
ing full clinical beneﬁts.33 Accurate genotype assignment
in the cohorts used for this study, reﬂected in the low HU
use rate found for the HbSC group, allowed an accurate
measure of HU usage rates, and demonstrated a much
higher HU treatment rate for children than previously
found.30 The more-recent data used for this study also
presumably reﬂect evolving trends in HU use for children
subsequent to safety studies.
The observed regional and treatment center differ-
ences in initiating HU therapy are unexplained. Possible
reasons may include variations in parental acceptance,
practice differences, barriers to access, limited treatment
center resources, or some combination of these factors.
Future studies should address this question. Another
important follow-up to this study will be to assess
outcomes of the increased HU use for children, statewide,
to determine if the established therapeutic beneﬁts of HU
treatment are realized in community health settings and
if the higher initiation rates observed in some regions
beneﬁt more individuals.
Publication of this article was supported by the Centers for
Disease Control and Prevention.
We thank Scott Miller and Scott Grosse for valuable
discussions. The study was designed by DGA, TL, NSG, YW,
and LSS. Data were collected and the manuscript drafted by
DGA, FT, and LSS. Newborn Screening Program results were
provided by MC. Statistical analyses were conducted by FT.
Department of Health authors had access to primary data. All
authors contributed to interpreting results and approved the
ﬁnal manuscript. This study was unsupported, but built upon
earlier work funded by the National Heart, Lung, and Blood
Institute/CDC (U50 DD000722). It was conducted with New
York State Department of Health IRB approval under protocol
#14-049.
No ﬁnancial disclosures were reported by the authors of
this paper.
Anders et al / Am J Prev Med 2016;51(1S1):S31–S38S38References
1. Charache S, Terrin ML, Moore RD, et al. Design of the multicenter
study of hydroxyurea in sickle cell anemia. Investigators of the
Multicenter Study of Hydroxyurea. Control Clin Trials. 1995;16(6):
432–446. http://dx.doi.org/10.1016/S0197-2456(95)00098-4.
2. Steinberg MH, McCarthy WF, Castro O, et al. The risks and beneﬁts of
long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-
up. Am J Hematol. 2010;85(6):403–408. http://dx.doi.org/10.1002/
ajh.21699.
3. Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on
mortality and morbidity in adult sickle cell anemia: risks and beneﬁts
up to 9 years of treatment. JAMA. 2003;289(13):1645–1651. http://dx.
doi.org/10.1001/jama.289.13.1645.
4. Voskaridou E, Christoulas D, Bilalis A, et al. The effect of prolonged
administration of hydroxyurea on morbidity and mortality in adult
patients with sickle cell syndromes: results of a 17-year, single-center
trial (LaSHS). Blood. 2010;115(12):2354–2363. http://dx.doi.org/10.1182/
blood-2009-05-221333.
5. Ferster A, Vermylen C, Cornu G, et al. Hydroxyurea for treatment of
severe sickle cell anemia: a pediatric clinical trial. Blood. 1996;88(6):
1960–1964.
6. Kinney TR, Helms RW, O’Branski EE, et al. Safety of hydroxyurea in
children with sickle cell anemia: results of the HUG-KIDS study,
a phase I/II trial. Pediatric Hydroxyurea Group. Blood. 1999;94(5):
1550–1554.
7. Wang WC, Ware RE, Miller ST, et al. Hydroxycarbamide in very
young children with sickle-cell anaemia: a multicentre, randomised,
controlled trial (BABY HUG). Lancet. 2011;377(9778):1663–1672.
http://dx.doi.org/10.1016/S0140-6736(11)60355-3.
8. Hankins JS, Ware RE, Rogers ZR, et al. Long-term hydroxyurea
therapy for infants with sickle cell anemia: the HUSOFT extension
study. Blood. 2005;106(7):2269–2275. http://dx.doi.org/10.1182/
blood-2004-12-4973.
9. Thornburg CD, Files BA, Luo Z, et al. Impact of hydroxyurea on
clinical events in the BABYHUG trial. Blood. 2012;120(22):4304–4310.
http://dx.doi.org/10.1182/blood-2012-03-419879.
10. Thornburg CD, Dixon N, Burgett S, et al. A pilot study of hydroxyurea
to prevent chronic organ damage in young children with sickle cell
anemia. Pediatr Blood Cancer. 2009;52(5):609–615. http://dx.doi.org/
10.1002/pbc.21738.
11. Thompson BW, Miller ST, Rogers ZR, et al. The pediatric hydroxyurea
phase III clinical trial (BABYHUG): challenges of study design. Pediatr
Blood Cancer. 2010;54(2):250–255.
12. Ware RE. How I use hydroxyurea to treat young patients with sickle
cell anemia. Blood. 2010;115(26):5300–5311. http://dx.doi.org/10.1182/
blood-2009-04-146852.
13. McGann PT, Flanagan JM, Howard TA, et al. Genotoxicity associated
with hydroxyurea exposure in infants with sickle cell anemia: results
from the BABY-HUG Phase III Clinical Trial. Pediatr Blood Cancer.
2012;59(2):254–257. http://dx.doi.org/10.1002/pbc.23365.
14. Wang WC, Helms RW, Lynn HS, et al. Effect of hydroxyurea on
growth in children with sickle cell anemia: results of the HUG-KIDS
Study. J Pediatr. 2002;140(2):225–229. http://dx.doi.org/10.1067/
mpd.2002.121383.
15. Rana S, Houston PE, Wang WC, et al. Hydroxyurea and growth
in young children with sickle cell disease. Pediatrics. 2014;134(3):
465–472. http://dx.doi.org/10.1542/peds.2014-0917.
16. Hankins JS, Aygun B, Nottage K, et al. From infancy to adolescence:
ﬁfteen years of continuous treatment with hydroxyurea in sickle cell
anemia. Medicine (Baltimore). 2014;93(28):e215. http://dx.doi.org/
10.1097/MD.0000000000000215.17. Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of
sickle cell disease: summary of the 2014 evidence-based report by
expert panel members. JAMA. 2014;312(10):1033–1048. http://dx.doi.
org/10.1001/jama.2014.10517.
18. Buchanan GR, Yawn BP, co-chairs; Sickle Cell Disease Guidelines
Expert Panel. Evidence-Based Management of Sickle Cell Disease,
Expert Panel Report 2014. Published September 8, 2014; www.nhlbi.
nih.gov/health-pro/guidelines/sickle-cell-disease-guidelines.
19. Green NS, Barral S. Emerging science of hydroxyurea therapy for
pediatric sickle cell disease. Pediatr Res. 2014;75:196–204.
20. Oyeku SO, Driscoll MC, Cohen HW, et al. Parental and other factors
associated with hydroxyurea use for pediatric sickle cell disease. Pediatr
Blood Cancer. 2013;60(4):653–658. http://dx.doi.org/10.1002/pbc.24381.
21. Lanzkron S, Haywood C, Hassell KL, Rand C. Provider barriers to
hydroxyurea use in adults with sickle cell disease: a survey of the Sickle
Cell Disease Adult Provider Network. J Natl Med Assoc. 2008;100(8):
968–973.
22. Boulet SL, Yanni EA, Creary MS, Olney RS. Health status and
healthcare use in a national sample of children with sickle cell disease.
Am J Prev Med. 2010;38(4 suppl):S528–S535. http://dx.doi.org/10.1016/
j.amepre.2010.01.003.
23. Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of
medication adherence and persistence using automated databases.
Pharmacoepidemiol Drug Saf. 2006;15(8):565–574; discussion 575-577.
http://dx.doi.org/10.1002/pds.1230.
24. Wang Y, Kennedy J, Caggana M, et al. Sickle cell disease incidence
among newborns in New York State by maternal race/ethnicity and
nativity. Genet Med. 2013;15(3):222–228. http://dx.doi.org/10.1038/
gim.2012.128.
25. Crawford DC, Caggana M, Harris KB, et al. Characterization of beta-
globin haplotypes using blood spots from a population-based cohort of
newborns with homozygous HbS. Genet Med. 2002;4(5):328–335. http:
//dx.doi.org/10.1097/00125817-200209000-00003.
26. Ender KL, Lee MT, Sheth S, et al. Fetal hemoglobin levels in African
American and Hispanic children with sickle cell disease at baseline and
in response to hydroxyurea. J Pediatr Hematol Oncol. 2011;33(7):
496–499. http://dx.doi.org/10.1097/MPH.0b013e31822dcc21.
27. Grosse SD, Boulet SL, Amendah DD, Oyeku SO. Administrative data
sets and health services research on hemoglobinopathies: a review of
the literature. Am J Prev Med. 2010;38(4 suppl):S557–S567. http://dx.
doi.org/10.1016/j.amepre.2009.12.015.
28. Lau HS, de Boer A, Beuning KS, Porsius A. Validation of pharmacy
records in drug exposure assessment. J Clin Epidemiol. 1997;50(5):
619–625. http://dx.doi.org/10.1016/S0895-4356(97)00040-1.
29. McKenzie DA, Semradek J, McFarland BH, Mullooly JP, McCamant
LE. The validity of medicaid pharmacy claims for estimating drug use
among elderly nursing home residents: the Oregon experience. J Clin
Epidemiol. 2000;53(12):1248–1257. http://dx.doi.org/10.1016/S0895-4356
(00)00259-6.
30. Tripathi A, Jerrell JM, Stallworth JR. Clinical complications in severe
pediatric sickle cell disease and the impact of hydroxyurea. Pediatr
Blood Cancer. 2011;56(1):90–94. http://dx.doi.org/10.1002/pbc.22822.
31. Ritho J, Liu H, Hartzema AG, Lottenberg R. Hydroxyurea use in
patients with sickle cell disease in a Medicaid population. Am J
Hematol. 2011;86(10):888–890. http://dx.doi.org/10.1002/ajh.22134.
32. Candrilli SD, O’Brien SH, Ware RE, Nahata MC, Seiber EE, Balk-
rishnan R. Hydroxyurea adherence and associated outcomes among
Medicaid enrollees with sickle cell disease. Am J Hematol. 2011;
86(3):273–277. http://dx.doi.org/10.1002/ajh.21968.
33. Thornburg CD, Calatroni A, Telen M, Kemper AR. Adherence to
hydroxyurea therapy in children with sickle cell anemia. J Pediatr.
2010;156(3):415–419. http://dx.doi.org/10.1016/j.jpeds.2009.09.044.www.ajpmonline.org
